← Human Trials & Peer-Reviewed Studies
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Plain-language guide to PMID 20493430 (2010): open-label randomized controlled trial of Angiotensin II Type 1 Receptor Blockers in 18 patients.
Key Facts
- PMID
- 20493430
- Journal
- European journal of internal medicine
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Ozaki N et al. (5 authors)
- DOI
- 10.1016/j.ejim.2010.01.014
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Angiotensin II Type 1 Receptor Blockers, published as a randomized controlled trial.
The researchers investigated the effects of 3 angiotensin II type 1 receptor blockers (ARBs)-telmisartan, candesartan, and valsartan-on metabolic parameters in hypertensive patients with type 2 diabetes.
Who Took Part
The abstract describes 18 patients taking part.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
A total of 308 hypertensive patients with diabetes were enrolled in their multicentre, randomized, open-label study.
How the Study Was Run
The design is described as randomized, open-label and multicenter.
Because people in this Angiotensin II Type 1 Receptor Blockers study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Everyone knew when Angiotensin II Type 1 Receptor Blockers was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
Running at several centres spread the Angiotensin II Type 1 Receptor Blockers study over different clinics and patient groups.
What Was Measured
Topics PubMed links to this paper include Adiponectin, Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Benzoates, Biphenyl Compounds, Blood Glucose and Blood Pressure.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Angiotensin II Type 1 Receptor Blockers in 18 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (European journal of internal medicine), a journal based in Netherlands.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.